WOCKPHARMA

Wockhardt Limited

Branded and generic formulations, APIs and a biosimilars pipeline

Healthcare›Healthcare›Pharmaceuticals & Biotechnology›Pharmaceuticals

wockhardt.com(opens the company website in a new tab)
Ask AI

Key metrics

Price as of 2026-10-16

Stock price
₹1954.90
Market cap
31,637 Cr
Stock P/E
77.4
P/B
6.41
Dividend yield
0.0%
ROE (FY26)
4.0%
ROCE (FY26)
6.1%
Operating margin (FY26)
12.6%
Debt / equity (FY26)
0.43
OCF / EBITDA (FY26)
59.8%
OCF / EBITDA (3Y)
54.2%

Full years shown; sign in free for the trailing twelve months. Learn about these metrics →

Price & valuation

Share price and valuation multiples (P/E, P/B and more) over time.

Loading price history…

Compare with peers

Loading peers…

What you need to know

Wockhardt makes and sells branded medicines and diabetes biosimilars such as insulin in India, the UK, Ireland and emerging markets, and is launching novel antibiotics developed in-house.

Company snapshot

21stBy market cap

Ranked among 119 companies in Pharmaceuticals.

Statement tables · Consolidated

Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.

Amounts in ₹ Cr · tap + to expand rows

Quarterly results

Quarterly · ₹ Cr · tap + rows to expand

MetricSept 2023Dec 2023Mar 2024Jun 2024Sept 2024Dec 2024Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026Jun 2026
Sales753 Cr701 Cr700 Cr739 Cr809 Cr721 Cr743 Cr738 Cr782 Cr888 Cr965 Cr929 Cr
Operating expenses (approx.)681 Cr664 Cr803 Cr648 Cr699 Cr593 Cr679 Cr666 Cr604 Cr711 Cr740 Cr737 Cr
EBITDA72 Cr37 Cr-103 Cr91 Cr110 Cr128 Cr64 Cr72 Cr178 Cr177 Cr225 Cr192 Cr
OPM %9.6%5.3%-14.7%12.3%13.6%17.8%8.6%9.8%22.8%19.9%23.3%20.7%
Other income24 Cr8 Cr54 Cr30 Cr9 Cr8 Cr15 Cr20 Cr21 Cr25 Cr45 Cr31 Cr
Interest76 Cr77 Cr73 Cr73 Cr73 Cr60 Cr48 Cr48 Cr55 Cr60 Cr50 Cr52 Cr
Depreciation55 Cr55 Cr58 Cr54 Cr55 Cr55 Cr53 Cr56 Cr53 Cr65 Cr53 Cr55 Cr
Profit before tax-35 Cr-87 Cr-180 Cr-6 Cr-9 Cr21 Cr-22 Cr-109 Cr91 Cr67 Cr189 Cr116 Cr
Tax %-108.6%1.1%1.7%-166.7%-77.8%4.8%-104.5%0.9%9.9%9.0%13.2%7.8%
Net profit-73 Cr-86 Cr-177 Cr-16 Cr-16 Cr20 Cr-45 Cr-108 Cr82 Cr61 Cr164 Cr107 Cr
EPS (₹)₹-5.37₹-5.75₹-11.64₹-0.95₹-1.47₹0.91₹-1.57₹-5.53₹4.81₹3.61₹10.23₹6.55

Profit & loss (annual)

Annual · last column is TTM · ₹ Cr · tap + to expand

MetricMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales4,015 Cr3,937 Cr4,158 Cr2,844 Cr2,708 Cr3,230 Cr2,651 Cr2,798 Cr3,012 Cr3,373 CrSign in free for the trailing twelve months
Operating expenses (approx.)4,002 Cr3,935 Cr4,049 Cr2,725 Cr2,771 Cr2,932 Cr2,550 Cr2,759 Cr2,619 Cr2,721 CrSign in free for the trailing twelve months
EBITDA13 Cr2 Cr110 Cr119 Cr-63 Cr298 Cr101 Cr39 Cr393 Cr652 CrSign in free for the trailing twelve months
OPM %0.3%0.0%2.6%4.2%-2.3%9.2%3.8%1.4%13.0%19.3%Sign in free for the trailing twelve months
Other income114 Cr120 Cr21 Cr39 Cr132 Cr20 Cr122 Cr83 Cr62 Cr111 CrSign in free for the trailing twelve months
Interest225 Cr255 Cr265 Cr276 Cr249 Cr299 Cr302 Cr305 Cr254 Cr213 CrSign in free for the trailing twelve months
Depreciation149 Cr150 Cr166 Cr224 Cr246 Cr247 Cr251 Cr223 Cr217 Cr227 CrSign in free for the trailing twelve months
Profit before tax-247 Cr-641 Cr-300 Cr-197 Cr916 Cr-411 Cr-624 Cr-420 Cr-16 Cr238 CrSign in free for the trailing twelve months
Tax %8.5%-4.0%27.9%77.9%24.8%32.1%0.5%-12.4%-256.3%16.4%Sign in free for the trailing twelve months
Net profit-226 Cr-667 Cr-217 Cr-43 Cr689 Cr-279 Cr-621 Cr-472 Cr-57 Cr199 CrSign in free for the trailing twelve months
EPS (₹)₹-17.71₹-55.01₹-17.58₹-6.25₹61.95₹-20.24₹-38.79₹-32.05₹-3.02₹13.12Sign in free for the trailing twelve months
Dividend payout %————0.1%————0.0%Sign in free for the trailing twelve months
Sign in free for the trailing twelve months

The latest four quarters added up, next to each full year

Balance sheet

Annual · ₹ Cr · tap + rows to expand

MetricMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity capital55 Cr55 Cr55 Cr55 Cr55 Cr72 Cr72 Cr77 Cr81 Cr81 Cr
Reserves3,281 Cr2,797 Cr2,619 Cr2,616 Cr3,321 Cr3,777 Cr3,282 Cr3,282 Cr4,272 Cr4,859 Cr
Borrowings3,853 Cr2,610 Cr2,453 Cr2,145 Cr1,569 Cr1,862 Cr1,887 Cr2,112 Cr1,859 Cr2,125 Cr
Other liabilities1,450 Cr2,354 Cr2,373 Cr2,977 Cr2,443 Cr2,179 Cr2,134 Cr1,875 Cr1,619 Cr1,209 Cr
Total liabilities9,022 Cr8,162 Cr7,831 Cr8,179 Cr7,773 Cr8,243 Cr7,683 Cr7,649 Cr8,135 Cr8,615 Cr
Fixed assets (net)1,942 Cr1,948 Cr2,125 Cr2,479 Cr2,311 Cr2,471 Cr2,022 Cr1,875 Cr1,718 Cr1,618 Cr
CWIP971 Cr1,039 Cr900 Cr836 Cr603 Cr389 Cr414 Cr434 Cr513 Cr671 Cr
Investments563 Cr214 Cr0.45 Cr0.45 Cr0.45 Cr0 Cr0 Cr0 Cr422 Cr412 Cr
Inventories1,108 Cr856 Cr819 Cr690 Cr799 Cr769 Cr658 Cr640 Cr725 Cr887 Cr
Trade receivables1,034 Cr962 Cr1,261 Cr1,243 Cr918 Cr918 Cr797 Cr618 Cr661 Cr588 Cr
Cash & bank964 Cr897 Cr397 Cr219 Cr232 Cr370 Cr90 Cr505 Cr112 Cr217 Cr
Other assets2,440 Cr2,246 Cr2,329 Cr2,711 Cr2,909 Cr3,326 Cr3,702 Cr3,577 Cr3,984 Cr4,222 Cr
Total assets9,022 Cr8,162 Cr7,831 Cr8,179 Cr7,773 Cr8,243 Cr7,683 Cr7,649 Cr8,135 Cr8,615 Cr

Cash flows

Annual · ₹ Cr · tap + rows to expand · last column includes FCF

MetricMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from operating activity-269 Cr68 Cr183 Cr649 Cr-287 Cr413 Cr153 Cr219 Cr-22 Cr390 Cr
Cash from investing-687 Cr630 Cr95 Cr-156 Cr1,470 Cr-201 Cr-125 Cr-137 Cr-783 Cr-241 Cr
Cash from financing1,254 Cr-769 Cr-776 Cr-680 Cr-1,171 Cr-71 Cr-315 Cr334 Cr409 Cr-54 Cr
Net cash flow298 Cr-71 Cr-499 Cr-186 Cr13 Cr138 Cr-280 Cr415 Cr-393 Cr105 Cr
Free cash flow (OCF − Capex)-680 Cr-239 Cr-92 Cr477 Cr-453 Cr201 Cr111 Cr160 Cr-387 Cr26 Cr

Ratios

MetricMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
ROCE %-0.3%-6.6%-0.6%1.5%21.9%-1.8%-5.8%-2.0%3.7%6.1%
ROE %-5.3%-19.0%-6.5%-2.3%18.2%-5.8%-15.3%-12.6%-1.0%4.0%
Debtor days9489110159123103109818063
Inventory days452359349405426457462377431479
Days payable218252358526308548609451352304
Cash conversion cycle3281961013924113-376159238
OCF / EBITDA %n.m.n.m.n.m.545.2%—138.6%151.5%n.m.-5.6%59.8%
OCF / EBITDA % (3 years)——n.m.n.m.n.m.218.8%82.9%179.2%65.7%54.2%
Debt / equity1.150.920.920.800.460.480.560.630.430.43
Current ratio2.291.260.980.680.730.760.560.741.211.61
Net debt / EBITDA225.74—18.7616.18—5.0117.7941.214.452.93